




Name	Ji Won Lee	
Current Position	Associate professor	
Country	Republic of Korea	
Major Field	Pediatric oncology	

Educational Background

Ph.D. (2010.3-2015.2) Seoul National University College of Medicine, Seoul, Korea

M.S. (2007.9-2009.8) Seoul National University College of Medicine, Seoul, Korea

M.D. (2000.3-2004.2) Ewha Woman's University College of Medicine, Seoul, Korea

Professional Experience

March, 2019-Present, Associate Professor, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

September, 2015-February, 2019, Assistant Professor, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

March, 2012-August 2015, Assistant Professor, Division of Hematology/oncology, Department of Pediatrics, Seoul National University Hospital, Seoul, Republic of Korea

2009-2011, Fellow, Division of Hematology/oncology, Department of Pediatrics, Seoul National University Hospital

2005-2009, Resident, Department of Pediatrics, Seoul National University Hospital

Other Experience and Professional Memberships

June, 2022-June, 2023, Visiting scholar, Ben May Department for Cancer Research, The University of Chicago

Main Scientific Publications

1. High-dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma. *Pediatr Blood Cancer*. 2023;70:e30233
2. Cho HW, Lee H, Ju HY, Yoo KH, Koo HH, Lim DH, Sung KW, Shin HJ, Suh YL, Lee JW. Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification. *J Korean Med Sci* 2022;37:e59.
3. Lee JW, Bae JS, Kim JH, Cho HW, Ju HY, Yoo KH, Koo HH, Woo SY, Kim S, Sung KW. Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment

-
- Outcomes in Patients with Neuroblastoma. *Cancer Res Treat* 2021.
4. Lee JW, Lim DH, Sung KW, Cho HW, Ju HY, Yoo KH, et al. Induction Chemotherapy Reduces Radiation Therapy Dose and Volume in the Treatment of Intracranial Germinoma: Results of the SMC-G13 Trial. *Int J Radiat Oncol Biol Phys*. 2020;108:649-56.
 5. Lee JW, Lim DH, Sung KW, Cho HW, Ju HY, Hyun JK, et al. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma. *Cancer Med*. 2020;9:5807-18.
 6. Seo ES, Lee EJ, Lee B, Shin M, Cho YS, Hyun JK, Cho HW, Ju HY, Yoo KH, Koo HH, Lee JW, Sung KW. Metastatic Burden Defines Clinically and Biologically Distinct Subgroups of Stage 4 High-Risk Neuroblastoma. *J Clin Med*. 2020;9.
 7. Lee E, Lee JW, Lee B, Park K, Shim J, Yoo KH, et al. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma. *BMC Med Genomics*. 2020;13:171.
 8. Lee JW, Kim NKD, Lee SH, Cho HW, Ma Y, Ju HY, et al. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors. *PLoS one*. 2019;14(11):e0224227.
 9. Lee B, Lee JW, Shim JH, Joung JG, Yun JW, Bae JS, et al. Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors. *Transl Oncol*. 2018; 11:1390-1397.
 10. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. *J Hematol Oncol*. 2017;10:108.
-